Valuation of Biotechnology Stage of Clinical Development is Most Important

Jeremy Webster, CA, CBV, ASA, is a Senior Vice President & Director in the Edmonton office of Deloitte & Touche. He has extensive experience in valuation and licensing for biotechnology companies and their assets.

Trevor Philippon, CA, and Mykhaylo Hotsaliuk, CA, are senior members of the valuation team at Deloitte & Touche.